Description
Relugolix, sold under the brand names Rexigo among others, is a gonadotropin-releasing hormone antagonist (GnRH receptor antagonist) medication which is used in the treatment of prostate cancer in men and uterine fibroids in women.
Relugolix was approved for use for the treatment of uterine fibroids in Japan in January 2019, and for the treatment of prostate cancer in the United States in December 2020.
Get Access To Rexigo (Relugolix) In India
Brand Name “Rexigo tablets” or Generic Name “Relugolix” can be imported for personal use under “Named Patient Program” treatment in Delhi, Mumbai, Kolkata, Chennai, Bangalore, Hyderabad, Ahmedabad, Pune, Surat, Jaipur, Coimbatore, Noida, Gurgaon, Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura and Sikkim, India. Contact us at support@southdelhipharma.com, southdelhipharma@gmail.com or call/WhatsApp at +91-9891296838 to get access as per norms.
